The availability of generic versions of Ambien (zolpidem, Sanofi-Aventis) in the US from April 2007 onwards has intensified competition for both existing and prospective players in the insomnia market. Following the discontinuation of three 5-HT antagonists in late-stage development over 20092010, orexin receptor antagonists now represent the most innovative candidates in the insomnia pipeline.
Reasons to Purchase
*Quantify the current and future size of the insomnia market in the seven major pharmaceutical markets.
*Identify potential licensing opportunities based on product portfolios and anticipated market needs.
*Understand the country-specific impact of key events in the insomnia market during the forecast period 2010 to 2019.
#N/A
Other selected research from the 'Markets' category:
Biotech Financing in the Credit Crisis: Strategies for a radically altered landscape
An overview of licensing trends in the US during 2006-08, and current/future biotech financing strategies in today’s changing economic climate. Learn More
Microscopy Markets
This report deals with the analysis of market segments of microscopes used in clinical and research laboratories. Learn More
Other selected research from the 'Neurological disorders' category:
Schizophrenia Market Forecast
Despite imminent generic erosion of blockbuster brands, the schizophrenia market will retain its value, supported by the uptake of premium priced depot formulations and new pipeline therapies to offset the... Learn More
Alzheimer's Disease Market Forecast
Current management of Alzheimer’s disease is wholly inadequate, providing only symptomatic benefit to patients in whom the underlying neurodegeneration continues unabated. However, with the launch of the first disease-modifying... Learn More